• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Incyte Corp (NQ: INCY )

    83.38 +1.04 (+1.26%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Incyte Corp

    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    16 17 Next >
    Biotech Investors: August's Key PDUFA Catalysts You Must Know
    Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
    Via Benzinga
    Expert Ratings for Incyte
    Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
    Via Benzinga
    New Indication Approval For Incyte "To Usher New Growth Avenue"
    Via Benzinga
    The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
    Via Benzinga
    4 Analysts Have This to Say About Incyte
    Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: 
    Via Benzinga
    Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
      
    Via Benzinga
    Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
    From Incyte
    Via Business Wire
    The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    Twitter And 3 Other Stocks Insiders Are Selling
    US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
    Via Benzinga
    Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
    Four pharmaceutical stocks, including three biotech movers, are making big moves. 
    Via Investor's Business Daily
    Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
    The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
    Via Benzinga
    7 Defensive Stocks to Buy for a Bear Market
    As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market. 
    Via InvestorPlace
    Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
    Via Benzinga
    The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
    CNBC 
    Via Benzinga
    Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
    Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. 
    Via Benzinga
    Insights On Incyte Corporation
    In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million... 
    Via Talk Markets
    Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
    From Incyte
    Via Business Wire
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
    A confirmed market uptrend is reeling as inflation's pain bites. 
    Via Investor's Business Daily
    Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
    Via Benzinga
    Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
    Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
    Via Benzinga
    Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
    The race is on in eczema treatment as the biggest name faces new rivals. 
    Via Investor's Business Daily
    FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
    The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
    Via Benzinga
    The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    < Previous 1 2
    ...
    6 7 8 9 10 11 12 13 14
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.